ARS Pharmaceuticals, Inc.
SPRY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671858
No open-market purchases or sales by ARS Pharmaceuticals, Inc. insiders were filed in the last 90 days; 208 institutions reported holding it in 13F filings for Q2 2026, worth $726.0M in total; Third Point is the only superinvestor holding it.
Holders of 5% or more of SPRY
Holders whose latest Schedule 13D or 13G filing reports 5% or more of ARS Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13D/A | 11.10%10.9M shares | – | Oct 1, 20251 filing | Oct 1, 2025 | SEC |
| Flynn James E | 13D/A | 7.75%7.61M shares | −1.04 ppfrom 8.79% | Mar 24, 20254 filings | Aug 1, 2025 | SEC |
| Rubric Capital Management LP | 13G | 6.27%6.20M shares | New | Feb 13, 20261 filing | Feb 13, 2026 | SEC |
| Millennium Management LLC | 13G/A | 6.00%5.92M shares | +0.60 ppfrom 5.40% | Mar 24, 20262 filings | Mar 31, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.10%5.01M shares | New | Jan 21, 20261 filing | Jan 21, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
9 Schedule 13D and 13G filings on ARS Pharmaceuticals, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 31, 20266:43 PM ET | Millennium Management LLCand 3 others | 13G/A | 6.00%5.92M shares | +0.60 ppfrom 5.40% | Mar 27, 2026 | SEC |
| Mar 24, 20264:18 PM ET | Millennium Management LLCand 2 others | 13G | 5.40%5.39M shares | New | Mar 17, 2026 | SEC |
| Feb 13, 20264:24 PM ET | Rubric Capital Management LPand 1 other | 13G | 6.27%6.20M shares | New | Dec 31, 2025 | SEC |
| Jan 21, 202612:30 PM ET | BlackRock, Inc. | 13G | 5.10%5.01M shares | New | Dec 31, 2025 | SEC |
| Oct 1, 20259:19 PM ET | Ra Capital Management, L.P.and 3 others | 13D/A | 11.10%10.9M shares | – | Sep 29, 2025 | SEC |
| Aug 1, 20256:06 PM ET | Flynn James Eand 5 others | 13D/A | 7.75%7.61M shares | −1.04 ppfrom 8.79% | Jul 30, 2025 | SEC |
| Jul 22, 20257:38 PM ET | Flynn James Eand 5 others | 13D/A | 8.79%8.63M shares | −1.11 ppfrom 9.90% | Jul 18, 2025 | SEC |
| Jul 2, 20258:24 AM ET | Flynn James Eand 5 others | 13D/A | 9.90%9.72M shares | −0.82 ppfrom 10.72% | Jul 2, 2025 | SEC |
| Mar 24, 20257:57 PM ET | Flynn James Eand 5 others | 13D/A | 10.72%10.5M shares | – | Mar 20, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell ARS Pharmaceuticals, Inc. shares.
No Form 144 notices for ARS Pharmaceuticals, Inc. are on file.